Marginal Zone Lymphoma: FDA Updates

May 28, 2019 – The U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID) in combination with rituximab (RITUXAN) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL). More Information.